RE: Omega Staff - LFT Costs4 Mar 2021 19:32
JAdam, on your post to me - That was not the point of the exercise - Omega have already stated why the 6 months figures where down - The point was to cleary illustrate how CK could possible get to a price point for the LFT - You can never get away with the GP%, and because that is all we have, along with some info on Innova, and the balance sheet from 2019/2020 (pre Covid).
You are asking a hypothetical question when you say we must look at the 'income'- Yes I agree for an overall business, but we have Covid figures with reduced income, second which is the crux is we have no idea of future income, as we do not know what a contract (s) look like for Covid related products.
The numbers you have stated are correct, but due to Covid and the whole business gearing up for Covid products, in some way they are pointless - It does not show the real picture, ie: gearing up for Omega to create product (s) that where not on their radar last Feb/March 2020. When you actually think about it, its remarkable what they have achieved in less than a year, and if if was not there would be many manufacturing.
Just go and look at the money that is going to Global Access Diagnostics, its frightening - That should tell you and everyone else who has lost faith what the end goal is, Soros Fund Managementare are not idiots, go and look into them and who is behind this.
https://find-and-update.company-information.service.gov.uk/company/12558218/charges
But we have the GP % of 64%, 2 years in a row - So, in this instance to work out a price point, we can only take a contract amount, be that 100 mil, 1 billion and use the GP%, because its been constant for two years, without Covid.
We also know NCYT is 83% GP (I haven't check myself) - I would suggest, due to reduce earnings in the first 6 months, CK will up his GP by 10%, maybe 15% - If that is the case, that makes any contract a lot more profitable.